MedPath

Efficacy and Safety of Fospropofol for Same-day Bidirectional Endoscopy in Elderly Patients

Phase 4
Not yet recruiting
Conditions
Elderly Patients
Interventions
Registration Number
NCT06251999
Lead Sponsor
Shanghai 6th People's Hospital
Brief Summary

Introduction: Fospropofol disodium is a novel prodrug that has improved pharmacokinetic and pharmacodynamic properties compared with propofol. This trial aims to compare the efficacy and safety of fospropofol versus propofol sedation for same-day bidirectional endoscopy in elderly patients.

Methods and analysis: This is a prospective, single-center, double-blind, randomized, propofol-controlled, non-inferiority trial. A total of 256 adult patients scheduled for same-day bidirectional endoscopy under sedation will be randomly allocated, in a 1:1 ratio, to a fospropofol group or a propofol group (n=128 in each group). All patients will receive analgesic pretreatment with sufentanil 5 μg. Two minutes later, an initial bolus dose of fospropofol 6.5 mg/kg or 1.5 mg/kg propofol and supplemental doses of fospropofol 1.6 mg/kg or 0.5 mg/kg propofol will be titrated as needed to the target sedation levels during the procedures. The primary outcome is the success rate of same-day bidirectional endoscopy. Secondary outcomes include the time to successful induction of sedation, duration, time to being fully alert, time to patient discharge, endoscopist satisfaction, patient satisfaction, and the top-up frequency and dosage of sedative medications. The safety endpoints consist of adverse events (AEs) concerning cough reflex, gag reflexes, body movement, muscular tremor, pain on injection. Sedation-related AEs, including episodes of desaturation, severe desaturation (SpO2 \< 90%), hypotension, severe hypotension (decrease in mean blood pressure ≥30% of baseline), and bradycardia, will be also recorded. Data will be analyzed on the intention-to-treat basis.

Discussion: The investigators hypothesize that the efficacy and safety of fospropofol sedation for elderly patients undergoing same-visit bidirectional endoscopy will not be inferior to that of propofol. The findings will provide daily practice of sedation regimens for same-day bidirectional endoscopy in elderly patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
256
Inclusion Criteria
  • 65 years or older
  • American Society of Anesthesiologists (ASA) physical status I to III
  • Body mass index (BMI) 18-30 kg/m2
  • Scheduled for same-day bidirectional endoscopy under sedation
Exclusion Criteria
  • Severe cardiovascular, pulmonary, renal, or liver diseases
  • Previous hypotension (systolic blood pressure ≤90 mmHg), bradycardia (heart rate <50 beats/min), or hypoxemia (SpO2 <90%)
  • Neurocognitive or psychiatric disorders
  • Contraindications to gastroscopy (gastric retention, long-term aspirin administration, etc.)
  • Hypersensitivity to study medications
  • Drug or alcohol misuse
  • Definite upper respiratory tract infection
  • Refusal for participation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
fospropofolfospropofol sedation-
propofolPropofol-
Primary Outcome Measures
NameTimeMethod
The success rate of same-day bidirectional endoscopyImmediate time after sedation emergence

The success rate of the gastrointestinal endoscopy was assessed according to the following criteria : 1) completion of the gastrointestinal endoscopy; 2) no need for rescue sedative/anesthetic, which means the top-up doses of the experimental drugs were administered no more than five times within any 15-min window from the initial administration to the end of the procedure.

Secondary Outcome Measures
NameTimeMethod
Incidence of adverse events (AEs) at timepoint 2Intraoperative (during sedation)

Episodes of desaturation, severe desaturation (SpO2 \< 90%), hypotension, severe hypotension (decrease in mean blood pressure ≥30% of baseline), and bradycardia.

Incidence of adverse events (AEs) at timepoint 3Intraoperative (the timepoint of sedation emergence)

Episodes of desaturation, severe desaturation (SpO2 \< 90%), hypotension, severe hypotension (decrease in mean blood pressure ≥30% of baseline), and bradycardia.

Incidence of adverse events (AEs) at timepoint 6Immediate time of hospital discharge

Episodes of desaturation, severe desaturation (SpO2 \< 90%), hypotension, severe hypotension (decrease in mean blood pressure ≥30% of baseline), and bradycardia.

The time to successful induction of sedationImmediate time after sedation emergence

the time counted from the start of drug administration to the achievement of a sedation score (MOAA/S ) ≤ 1

Time to being fully alertImmediate time after sedation emergence

the time from gastrointestinal endoscopy extraction or/and the time from the last drug administration to a MOAA/S score of 5 on three consecutive measurements;

Time to patient dischargeImmediate time of hospital discharge

Time to patient discharge

Endoscopist's satisfaction questionnaireImmediate time after sedation procedure completion

Endoscopist's satisfaction

Patient's satisfaction questionnaireImmediate time of hospital discharge

Patient's satisfaction

The top-up frequency and dosage of sedative medicationsImmediate time after sedation emergence

The top-up frequency and dosage of sedative medications

Incidence of adverse events (AEs) at timepoint 1baseline (Prior to sedation)

Episodes of desaturation, severe desaturation (SpO2 \< 90%), hypotension, severe hypotension (decrease in mean blood pressure ≥30% of baseline), and bradycardia.

Incidence of adverse events (AEs) at timepoint 415 min in post-anesthesia care unit

Episodes of desaturation, severe desaturation (SpO2 \< 90%), hypotension, severe hypotension (decrease in mean blood pressure ≥30% of baseline), and bradycardia.

Incidence of adverse events (AEs) at timepoint 530 min in post-anesthesia care unit

Episodes of desaturation, severe desaturation (SpO2 \< 90%), hypotension, severe hypotension (decrease in mean blood pressure ≥30% of baseline), and bradycardia.

© Copyright 2025. All Rights Reserved by MedPath